ANTIPLATELET MEDICATIONS IN HEMODIALYSIS: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/8kz2bg50Keywords:
Anti platelet medications, antiplatelet therapy, hemodialysisAbstract
Background: Vascular access failure is a common complication seen among hemodialysis (HD) patients. Antiplatelet (AP) medications are often prescribed to help reduce thrombosis and increase vascular access patency. Studies on AP agents evaluating the bleeding risk for HD patients have produced inconsistent results. We aimed to investigate the utilization of AP medications among patients who undergo hemodialysis (HD). We performed a systematic review and meta-analysis of observational studies on AP medicaations used in HD therapy.
Methods: This systematic review used Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 as standards. Inclusion criteria for literature eligibility are full-text literature, written in english, and published between 2014 and 2024. Exclusion criteria used for this study were editorials, review articles and identical journal that has been published, and submissions without DOI. Literatures were collected from online reference sources like Pubmed and SagePub.
Result: In the PubMed database, the results of our search brought up 23 articles, whereas the results of our search on SagePub brought up 19 articles. The results of the search conducted for the last year of 2014 yielded a total 9 articles for PubMed and 5 articles for SagePub. In the end, we compiled a total of 5 papers, 4 of which came from PubMed and 1 of which came from SagePub. We included five research that met the criteria.
Conclusion: AP medications are given in HD patients with high cardiovascular commorbidities to increase vascular patency and prevent thrombosis. Aspirin and P2Y12 inhibitors (PI) such as clopidogrel are commonly used. AP medications might cause shortened longevity of AV access for HD patients. The benefits of AP therapy for cardiovascular protection needs to be evaluated along with its possible effect on AVG outcomes.
References
Locham S, Beaulieu RJ, Dakour-Aridi H, Nejim B, Malas MB. Role of antiplatelet therapy in the durability of hemodialysis access. J Nephrol
Wang Q, Xie X, Xu G. The risk of bleeding for antiplatelet agents in Haemodialysis patients a Meta-analysis. BMC Nephrol
Nagaraj A, Skummer PT, Gunasekaran V, Johnson C, Roza A, Klinger D, et al. Role of Antiplatelet Therapy in Hemodialysis Arteriovenous Graft Secondary Patency Following Successful Percutaneous Thrombectomy. Cardiovasc Intervent Radiol
Shimizu A, Sonoda S, Muraoka Y, Setoyama K, Inoue K, Miura T, et al. Bleeding and ischemic events during dual antiplatelet therapy after second-generation drug-eluting stent implantation in hemodialysis patients. Journal of Cardiology
Yeh CH, Huang TS, Wang YC, Huang PF, Huang TY, Chen TP, et al. Initiation of antiplatelet medication after surgical thrombectomy jeopardized arteriovenous graft longevity. 2017;
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Journal of Advanced Research in Medical and Health Science (ISSN 2208-2425)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
